|
|---|
|
Francescone R,
Barbosa Vendramini-Costa D,
Franco-Barraza J,
Wagner J,
Muir A,
Lau AN,
Gabitova L,
Pazina T,
Gupta S,
Luong T,
Rollins D,
Malik R,
Thapa RJ,
Restifo D,
Zhou Y,
Cai KQ,
Hensley HH,
Tan Y,
Kruger WD,
Devarajan K,
Balachandran S,
Klein-Szanto AJ,
Wang H,
El-Deiry WS,
Vander Heiden MG,
Peri S,
Campbell KS,
Astsaturov I,
Cukierman E. Netrin G1 promotes pancreatic tumorigenesis through cancer associated fibroblast driven nutritional support and immunosuppression.
Cancer Discov. 2021 Feb;11(2)
:446-479. PMC ID:PMC7858242. |
|
Pazina T,
MacFarlane AW,
Bernabei L,
Dulaimi E,
Kotcher R,
Yam C,
Bezman NA,
Robbins MD,
Ross EA,
Campbell KS,
Cohen AD. Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma.
Cancers (Basel). 2021 Jan 10;13(2)
. PMC ID:PMC7827733. |
|
Pazina T,
James AM,
Colby KB,
Yang Y,
Gale A,
Jhatakia A,
Kearney AY,
Graziano RF,
Bezman NA,
Robbins MD,
Cohen AD,
Campbell KS. Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma.
Cancer Immunol Res. 2019 Oct;7(10)
:1633-1646. PMC ID:PMC6774869. |
|
Campbell KS,
Cohen AD,
Pazina T. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Front Immunol. 2018 ;9
:2551. PMC ID:PMC6230619. |
|
Pazina T,
James AM,
MacFarlane AWIv,
Bezman NA,
Henning KA,
Bee C,
Graziano RF,
Robbins MD,
Cohen AD,
Campbell KS. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms.
OncoImmunology. 2017 Sep;6(9)
:e1339853. PMC ID:PMC5599094. |
|
Pazina T,
Shemesh A,
Brusilovsky M,
Porgador A,
Campbell KS. Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression.
Front Immunol. 2017 March;8
:369. PMC ID:PMC5371597. |
|
Lerner MB,
D'Souza J,
Pazina T,
Dailey J,
Goldsmith BR,
Robinson MK,
Johnson ATC. Hybrids of a Genetically Engineered Antibody and a Carbon Nanotube Transistor for Detection of Prostate Cancer Biomarkers.
Acs Nano. 2012 Jun;6(6)
:5143-5149. PMC ID:PMC3383883. |
|
Faculty
Publications
